Market Intelligence, Clinical Progress, and High-Purity Reagents for Oncology and Pancreatic Cancer Development.
Background on PRSS3 (Mesotrypsin)
PRSS3 (also known as Mesotrypsin or Trypsinogen-4) is a serine protease belonging to the Peptidase S1 family. It is characterized by unique resistance to natural protease inhibitors and elevated expression in pancreatic ductal adenocarcinoma (PDAC), where it drives invasion and metastasis through extracellular matrix (ECM) degradation. Known genetic variations include dbSNP:rs11547028, dbSNP:rs855581, and dbSNP:rs1063273. Unlike digestive isoforms PRSS1/PRSS2, PRSS3 exhibits distinct substrate specificity, making it an attractive oncology target with potential for reduced gastrointestinal toxicity.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for PRSS3 drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | PRSS3 Recombinant Protein (Active & Zymogen Forms) High purity (>95%), Endotoxin <1 EU/µg, Sequence Verified. HEK293 expressed for authentic glycosylation. Available in pro-enzyme and auto-processed active forms. |
View PRSS3 Products |
| Gene Delivery | PRSS3 Lentivirus / Promise-ORF Full-length ORF with native signal peptide for stable cell line generation and secreted expression. |
View PRSS3 Products |
| Benchmark Ab | Anti-PRSS3 Control Antibody (Research Grade) Recombinant positive control for binding, neutralization, Western Blot, and capture assays. Sequence verified. |
View PRSS3 Products |
| Validator | PRSS3 siRNA Set For knockdown verification and target-specificity confirmation in cellular assays. |
View PRSS3 Products |
| Related Target: PRSS1 | PRSS1 (Trypsin-1) High-homology paralog; mandatory for selectivity counter-screening and pancreatic toxicity assessment. |
View PRSS1 Products |
| Related Target: F2R | F2R (PAR1) Downstream signaling mediator of PRSS3-driven invasion; suitable for functional mechanism assays. |
View F2R Products |
| Related Target: SPINK1 | SPINK1 (Serine Peptidase Inhibitor Kazal Type 1) Endogenous inhibitor; PRSS3 resistance to SPINK1 is a key functional differentiator. |
View SPINK1 Products |
| Related Target: TMPRSS2 | Transmembrane serine protease; related family member for broad protease panel screening. | View TMPRSS2 Products |
| Related Target: MMP9 | Matrix metalloproteinase-9; synergistic ECM remodeling partner in tumor microenvironment. | View MMP9 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Zymogen auto-activation control and mechanistic studies | Dual-form offering: Pro-PRSS3 (uncleaved, inactive) and Active-PRSS3 (auto-processed) with N-terminal sequencing verification. Purity >95% by SDS-PAGE and HPLC. |
| Selectivity over PRSS1/PRSS2 paralogs (off-target safety) | Human PRSS1, PRSS2, and PRSS3 homolog proteins available; >95% purity, mass spec verified for precise selectivity profiling. |
| Cross-species (cyno/mouse/human) evaluation | Human / Mouse / Cynomolgus ortholog PRSS3 proteins; sequence-aligned, endotoxin-controlled. |
| Lack of neutralizing controls and assay standardization | Research-grade anti-PRSS3 antibody included for functional blockade calibration and assay benchmarking. |
| False positives from non-specific inhibition | PRSS3 siRNA set included for orthogonal target engagement confirmation in cell-based assays. |
| Enzymatic assay reliability (active vs. zymogen) | HEK293 expressed to preserve native glycosylation; theoretical MW confirmed; active enzyme preparations stable for kinetic studies. |
Live PRSS3 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for PRSS3-targeted therapeutics is intensifying, with discovery programs shifting focus from biomarker validation to first-in-class small molecule and biologic inhibitors. PRSS3 has emerged as a critical node in ECM degradation and tumor microenvironment (TME) remodeling, driving invasion and metastasis in refractory cancers such as pancreatic ductal adenocarcinoma (PDAC), prostate cancer, and breast cancer. Unlike digestive trypsins (PRSS1/PRSS2), PRSS3 exhibits unique resistance to canonical serpins, enabling a favorable safety profile with reduced gastrointestinal toxicity. The next wave of R&D is targeting paralog-selective inhibition, zymogen activation mechanisms, and combination strategies with chemotherapy or immunotherapy. First-generation compounds are entering preclinical optimization, and collaborations between academic consortia and specialized biotechs are expanding. Key indications include metastatic solid tumors, chronic pancreatitis, and hereditary pancreatitis.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule Inhibitors | Academic spin-offs, early biotech | Pancreatic Cancer (PDAC), Colorectal Cancer, Chronic Pancreatitis | Enzymatic activity assay with active vs. zymogen protein (>95% purity for accurate kinetic data) |
| Neutralizing / Monoclonal Antibodies | Preclinical biopharma, immunotherapy-focused biotech | Solid Tumors (e.g., prostate, breast, pancreatic), Inflammatory Conditions | Epitope mapping and binding assays (need HEK293-expressed, native-folded antigen) |
| Covalent Serine Traps | Specialized protease biotechs | Metastatic solid tumors | Time-dependent inactivation studies (need stable active enzyme preparations) |
| Gene Therapy / RNAi | RNA therapeutics developers, early discovery | Hereditary Pancreatitis, Refractory Tumors | Cellular knockdown validation (need validated siRNA controls) |
| Biomarker / Companion Dx | Academic research consortia | PDAC prognosis | Immunoassay development (need high-purity zymogen antigen) |